Low testosterone levels in aging men are associated with insulin resistance. Mitochondrial dysfunction, changes in glycogen metabolism, and lipid accumulation are linked to insulin resistance in skeletal muscle. In this randomized, double-blinded, placebo-controlled study, we investigated the effects of six-month testosterone replacement therapy (TRT) and strength training (ST) on mitochondrial, glycogen, and lipid droplet (LD) content in skeletal muscle of aging men with subnormal bioavailable testosterone (BioT) levels. Mitochondrial, glycogen, and LD volume fractions in muscle biopsies were estimated by transmission electron microscopy. Insulin sensitivity (insulin-stimulated Rd) and body composition were assessed by euglycemic-hyperinsulinemic clamp and dual X-ray absorptiometry, respectively. TRT significantly increased total testosterone levels, BioT, and lean body mass (LBM) (p < 0.05), whereas percent body fat decreased (p < 0.05), and insulin sensitivity was unchanged. Baseline mitochondrial volume fraction correlated inversely with percent body fat (q = À0.43; p = 0.003). D-mitochondrial fraction correlated positively with D-total testosterone (q = 0.70; p = 0.02), and D-glycogen fraction correlated inversely with D-LBM (q = À0.83; p = 0.002) during six-month TRT, but no significant changes were observed in mitochondrial, glycogen, and LD volume fractions during TRT and ST. In conclusion, in this exploratory small-scale study, the beneficial effects of six-month TRT on total testosterone, LBM, and percent body fat were not followed by significant changes in fractions of mitochondria, glycogen, or lipid in skeletal muscle of aging men with lowered testosterone levels. Six-month ST or combined three-month ST+TRT did not change intramyocellular mitochondria, glycogen, and LD fractions compared to placebo. However, further studies with a larger sample size are needed.
INTRODUCTION
Aging men often have lower bioavailable testosterone (BioT) levels compared to a young reference population (Frost et al., 2013) . The age-related decline in testosterone levels is associated with reduced muscle mass (Frost et al., 2014) , increased abdominal adiposity (Glintborg et al., 2014) , and insulin resistance (Grossmann, 2011) . Mitochondrial dysfunction was reported in individuals with insulin resistance, as genes and proteins involved in mitochondrial oxidative metabolism (Hwang et al., 2010; Giebelstein et al., 2012) and biogenesis (Mootha et al., 2003; Patti et al., 2003) were downregulated in skeletal muscle biopsies. This reduction in mitochondrial capacity can result in decreased muscular lipid oxidation and increased lipid accumulation (Petersen et al., 2003; Lowell & Shulman, 2005) and subsequently suppress insulin signaling and reduce glycogen synthesis (Lowell & Shulman, 2005) . In accordance, obese subjects with type 2 diabetes mellitus (T2D) had lower intramyocellular volume fraction of glycogen compared to obese normoglycemic participants (Levin et al., 2001; Carey et al., 2003) ; however, similar glycogen volume fraction has also been reported (Nielsen et al., 2010) . A cross-sectional study in aging men reported positive associations between endogenous testosterone levels and insulin sensitivity, aerobic capacity (VO 2max ), and expression of mitochondrial oxidative phosphorylation genes from muscle biopsies (Pitteloud et al., 2005) . Recently, we observed increased lean body mass (LBM) and reduced subcutaneous fat deposits (Frederiksen et al., 2012a,b) during six-month testosterone replacement therapy (TRT) in aging men; however, insulin-stimulated rate of glucose disposal (Rd) was unchanged (Frederiksen et al., 2012a,b) . Moreover, we reported that strength training (ST) for six months increased muscle strength in aging men with lowered testosterone levels and abdominal obesity, whereas lean body mass (LBM) was unchanged (Kvorning et al., 2013) . To the best of our knowledge, there are no previous human data on adaptations in mitochondrial, glycogen, and lipid droplet (LD) content of skeletal muscle in the aging male during TRT, placebo, and ST, but animal studies reported that testosterone supplementation increased skeletal muscle mitochondrial biogenesis in male mice (Usui et al., 2014) and glycogenesis in castrated male rats (Ramamani et al., 1999) .
In this study, we investigated effects of TRT, placebo, and ST on volume fraction of mitochondria, glycogen, and LDs in skeletal muscle biopsies from aging men with lowered testosterone levels. Furthermore, we examined the associations between intramyocellular volume fraction of mitochondria, glycogen, and LDs and body composition, circulating testosterone, insulin-stimulated Rd, and triglyceride.
MATERIALS AND METHODS
We previously published effects of six-month TRT on body composition, substrate metabolism, and insulin sensitivity in a single-center, randomized, placebo-controlled, double-blinded study in men aged 60-78 years with lowered bioavailable testosterone (BioT) and waist circumference (WC) >94 cm (Frederiksen et al., 2012a,b) . The cutoff level for BioT was defined as <7.3 nmol/L based on observations from a comprehensively characterized reference population of men aged 20-30 years (Nielsen et al., 2007) . Exclusion criteria were hematocrit >50%, prostate cancer or prostate-specific antigen >3 ng/dL, previous or ongoing malignant disease, severe ischemic heart or respiratory disease, diabetes mellitus, alcohol or drug abuse, abnormal routine blood samples (TSH, ionized calcium, liver, and kidney function), treatment with 5-a-reductase inhibitors, morphine, or oral glucocorticoids (Frederiksen et al., 2012a,b) . The study was conducted at Odense University Hospital, and screening was started in January 2008 and ended in September 2009. This study included all data on skeletal muscle volume fraction of mitochondria, glycogen, and LD on all available muscle biopsies at baseline (n = 45) and on the effect of TRT, placebo, and ST (Fig. 1) . Information on intramuscular fractions of mitochondria, glycogen, and lipid droplet is not available from dropout participants, as there was no available muscle biopsy from these men.
Ethics
The study was approved by the local ethics committee (Project ID S-20070051), the Danish Medicines Agency (Journal No: 2612-3474) , and declared in ClinicalTrials.gov (NCT00700024) and performed in accordance with the 1964 Helsinki Declaration. All participants gave written informed consent at screening visit.
Study protocol (Fig. 2) Participants were randomly allocated to receive testosterone gel (5 g of gel/50 mg Testim, Ipsen, Paris, France), placebo gel per day, or strength training before entry to the groups. After three months of ST, the ST group was further randomized into two groups receiving ST+TRT or ST+placebo (Fig. 2) . Randomization list, medicine labeling, randomization, and code break envelopes were generated by Ipsen Scandinavia (Krista, Sweden) (Frederiksen et al., 2012a,b) . Sham titrations in both the TRT group and the placebo were externally handled to ensure continued blinding. If BioT was <7.3 nmol/L after three weeks of intervention, the dose was increased to 10 g gel (100 mg Testim or placebo). Five of 11 participants in the TRT group were increased to 10 g Testim gel, and in the placebo group, the dose was increased to 10 g placebo gel in all 13 participants at the three-week safety check. Participants were informed not to change their diet and refrain from any self-initiated physical exercise training; however, they were permitted to continue other habitual activities throughout the study period.
Strength training
The training group performed 5 min of standardized warm-up on a stationary bicycle with low resistance (approximately 100 W), followed by a progressive heavy ST program of exercises for the entire body with increased training loads at the start of every other week (Kvorning et al., 2013) . All training sessions were supervised, and participants engaged in a minimum of two of three weekly training sessions (mean AE SD training adherence 75 AE 8%) (Kvorning et al., 2013) .
Testosterone and SHBG
Testosterone levels were measured in the morning in the fasting state by liquid chromatography-tandem mass spectrometry (LC-MS) after ether extraction. For testosterone measurements, the intra-assay coefficient of variation (CV) was less than AE10% for total testosterone >0.2 nmol/L and less than AE30% in the range between 0.1 and 0.2 nmol/L (Frederiksen et al., 2012a,b) . Sex hormone binding globulin (SHBG) was measured by auto-DELFIA assay, and BioT was calculated according to the formulas of Vermeulen (Vermeulen et al., 1999) . The German Society for Clinical Chemistry and Laboratory Medicine (DGKL-Ring trial) undertook the external quality control of the LC-MS measurements.
Dual X-ray absorptiometry (DXA)
Total fat mass, central fat mass, and lean body mass were measured by DXA using a Hologic Discovery device (Waltham, MA, USA). The CV was 0.8% for total fat mass and 0.6% for lean body mass (Frederiksen et al., 2012a,b) .
Euglycemic-hyperinsulinemic clamp
After an overnight fast an euglycemic-hyperinsulinemic clamp was performed as previously described (Frederiksen et al., 2012a,b) . In brief, a 120-min basal tracer equilibration period was followed by the infusion of insulin at a rate of 40 mU/m 2 / min for 180 min. Euglycemia was maintained using a variable infusion rate of 20% glucose based on bedside plasma glucose measurements, and physiological hyperinsulinemia was obtained at approximately 400 pmol/L during the insulin-stimulated period. Plasma glucose, serum insulin, and plasma free fatty acids (FFA) concentrations were measured as previously described (Hojlund et al., 2006; Frederiksen et al., 2012a,b distribution volume of 200 mL/kg body weight and a pool fraction of 0.65 (Hother-Nielsen et al., 1996) . A muscle sample was obtained from the vastus lateralis muscle in the resting, basal state using a Bergstr€ om needle with suction under local anesthesia (10-15 mL lidocaine subcutaneously).
Transmission electron microscopy (TEM) and skeletal muscle content Muscle biopsies were fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate-buffered (pH 7.3) fixative for 24 h at 4°C and rinsed in 0.1 M sodium cacodylate buffer four times for a duration of 15 min. Following rinsing, the muscle biopsies were post-fixed with 1% osmium tetroxide in 0.1 M sodium cacodylate buffer for 90 min at 4°C. Subsequently, muscle biopsies were washed once in 0.1 M sodium cacodylate buffer and twice in sterile water at 4°C. The samples were dehydrated through a graded series of alcohol at 4-20°C, infiltrated with graded mixtures of propylene oxide and epon at 20°C, and finally embedded in 100% epon at 30°C for 90 min and 60°C for 2 days. Tissue blocks were cut into ultrathin sections using a Leica ultramicrotome separated by 60 nm. The sections were grid contrasted with uranyl acetate (3% in H 2 O for 14 min at 60°C) and lead citrate (for 6 min at room temperature). Sections were photographed in a JEM-1400 plus transmission electron microscope (120 kV) with a Quemesa camera (Olympus Soft Imaging Solutions, M€ unster, Germany). Ten micrographs per muscle biopsy were photographed in a randomized systematic order for stereological point counting. Micrographs were photographed at a magnification of 95 000. A representative micrograph with mitochondria, glycogen, and LD is shown in Fig. 3 . A grid was superimposed over the micrograph in the ITEM computer software (Olympus Soft Imaging Solutions, M€ unster, Germany) and included test points, defined as two intersecting grid lines. According to standard stereological principles, volume fraction of mitochondria and LD was estimated by counting the test points touching the given structure of interest and dividing them by the total number of test points hitting muscle fibers (Weibel, 1979; Gundersen et al., 1988) . Glycogen volume fraction (V V ) was determined as proposed by Weibel (Weibel, 1980) , here the effect of section thickness was taken into account
where A A is the glycogen area fraction, t is the section thickness (60 nm), B A is the boundary length density, N A is the number of particles per area, and H is the average glycogen profile diameter. Glycogen particles were assumed to be spherical (Melendez-Hevia et al., 1993) . The average glycogen profile diameter was measured using ITEM software. This was done blinded by the first author. Volume fractions of mitochondria and glycogen were assessed in grid sizes with squares of 500 9 500 nm (corresponding to 0.25 lm 2 , and density test point of 330/micrograph), and LDs were evaluated in grid sizes with squares of 125 9 125 nm (corresponding to 0.016 lm 2 , and density test point of 5460/micrograph), hence ensuring the principle of Cavalieri (Broskey et al., 2013) .
Assessment of cardiorespiratory fitness VO 2max was initially determined by an incremental test to exhaustion, but due to general discomfort, the maximal test was replaced by the Astrand submaximal cycle test (Astrand & Ryhming, 1954 ) (Online: n = 3, Astrand: n = 18). Prior to both tests, subjects performed a 6-min standardized warm-up at 60 W. The initial workload in the incremental online test was 60-120 W for 3-min, followed by 3-min with additional 30 W. Thereafter, power output was increased by 30 W every minute until exhaustion. VO 2 was calculated continuously throughout the test using a mixing chamber system (Oxycon Pro, Erich JAE-GER GnbH, Hoechberg, Germany), and VO 2max was defined as the highest mean VO 2 over 30 sec. In the submaximal test, VO 2max was determined from the Astrand nomogram and agecorrected (Astrand & Ryhming, 1954) .
Statistical analyses
Sample size was determined by the effect of TRT on lean body mass (Frederiksen et al., 2012a,b) . Data were not normally distributed. Data are presented as median and interquartile range (IQR). Differences at baseline, between, and within groups were analyzed with Mann-Whitney U-test for unpaired data and Wilcoxon's signed-rank test for paired data. Delta (D) values were calculated as post-treatment minus pre-treatment level. The effect of TRT and placebo were analyzed by comparing D-values of skeletal muscle mitochondrial, glycogen, and lipid content, Dbiochemical variables, and D-body composition using MannWhitney U-test as described by Altman, (2010). Spearman's nonparametric q correlation coefficient was performed estimating bivariate associations between intramyocellular mitochondrial, glycogen, and lipid volume fraction and biochemical variables, and body composition at baseline and after intervention. Statistics were performed using STATA version 14.2 (StataCorp, College Station, TX, USA), and p-values <0.05 were considered significant.
RESULTS

Changes in clinical and metabolic characteristics during TRT and placebo
In consistency with the entire study population (Frederiksen et al., 2012a,b) , we found no significant difference in biochemical assessments, body composition, insulin-stimulated Rd (Table 1) , or aerobic power (VO 2max ) (data not shown) between TRT, placebo, or ST at baseline. In line with previous papers (Frederiksen et al., 2012a,b; Petersson et al., 2014) , we also found that TRT significantly increased total testosterone, BioT, 550 Andrology, 2018, 6, 547-555 and LBM, and decreased percent body fat, but had no effect on insulin sensitivity measured as insulin-stimulated Rd or the ability of insulin to suppress FFA in this subgroup of individuals with attainable muscle biopsies (Table S1 ).
Skeletal muscle composition at baseline and during TRT, placebo, and ST (Table 2) Mitochondrial and glycogen volume fractions were comparable between TRT and placebo before treatment, but the volume fraction of LDs was higher in the TRT group compared to placebo (p < 0.05). No placebo-controlled change was found in skeletal muscle volume fraction of mitochondria, glycogen, and LDs in response to three-and six-month TRT, three-and sixmonth ST, or three-month combined ST+TRT.
Baseline associations (Table 3) In all available muscle biopsies at baseline (n = 45), mitochondrial fraction was inversely associated with percent body fat and circulating fasting FFA levels and tended to correlate positively with insulin-stimulated Rd (p = 0.06). Glycogen fraction was positively associated with circulating triglyceride levels and tended to correlate inversely with insulin-stimulated Rd (p = 0.09). LD fraction was positively associated with circulating triglyceride levels and inversely with SHBG levels.
Associations of changes during TRT and placebo
months
In the TRT group (n = 11), D-mitochondrial fraction was positively associated with total testosterone, and D-glycogen fraction was negatively associated with D-insulin-stimulated Rd (Table S2) .
No significant associations were found during placebo (n = 13), except D-glycogen fraction was negatively associated with insulin sensitivity (Table S3) .
In the TRT group (n = 11), we found that D-mitochondrial fraction was positively associated with D-total testosterone, Dinsulin-stimulated Rd, and correlated inversely with D-insulinstimulated FFA levels (Table 4) . Moreover, the TRT-induced increment in D-LBM correlated inversely with D-glycogen fraction. D-LD fraction was negatively associated with D-insulinstimulated-FFA (Table 4) .
In the placebo group (n = 13), D-glycogen fraction also correlated inversely with D-LBM, and D-LD fraction was negatively associated with D-insulin-stimulated Rd (Table S5) .
Associations of changes during ST
In the ST group (n = 14), D-mitochondrial fraction was positively associated with D-LBM and inversely with D-fat percentage, and D-glycogen fraction was positively associated with Dinsulin sensitivity Rd during three months (Table S4) .
After randomization of ST group into ST+TRT (n = 7) and ST+placebo (n = 7), the groups were too small for assessing associations after six months.
DISCUSSION
In this RCT, we investigated the effects of six-month TRT, placebo, and ST on volume fractions of mitochondria, glycogen, and LD in skeletal muscle biopsies from aging men with lowered testosterone levels. TRT significantly increased total testosterone levels and LBM, whereas percent body fat decreased, and insulin-stimulated Rd was unchanged. We found that baseline mitochondrial fraction was significantly inversely correlated with percent body fat. D-mitochondrial fraction was positively associated with both D-total testosterone, and D-glycogen fraction correlated inversely with D-LBM during six-month TRT, but no significant changes in mitochondrial, glycogen, and LD fractions were detected during TRT.
Our observation of an inverse baseline association between mitochondrial fraction and percent body fat was in accordance with a recent study by Bharadwaj et al., (2015) , where mitochondrial content correlated negatively with percent body fat in aging men. However, Bharadwaj et al. used citrate synthase activity as a biochemical marker of mitochondrial content instead of the gold standard method, TEM (Larsen et al., 2012) . We found that changes in mitochondrial fraction were positively associated with changes in total testosterone during TRT, but skeletal muscle mitochondrial fraction was not significantly affected. Our results were compatible with previous data from the same study cohort, where TRT resulted in unchanged levels of mRNA and proteins involved in mitochondrial biogenesis (Petersson et al., 2014) . Despite clinical relevant increase in testosterone levels, we observed no significant change in glycogen fraction during TRT. In contrast, an experimental rat study observed that testosterone deficiency was associated with decreased glycogen storage and synthesis in skeletal muscle at baseline, and glycogen stores were normalized in response to 30 days high-dose testosterone supplementation (Ramamani et al., 1999) . The discrepancy between study observations may be a result of non-physiological testosterone levels in an experimental animal study population (Ramamani et al., 1999) .
We cannot fully explain the lack of improvement in glycogen fraction and insulin-stimulated Rd during TRT (Frederiksen et al., 2012a,b) , as we saw an advantageous increase in LBM (Frederiksen et al., 2012a) and decreased total fat mass (Frederiksen et al., 2012a). However, visceral adipose tissue deposit was unchanged during TRT, and serum adiponectin levels and subcutaneous fat deposits were reduced (Frederiksen et al., 2012b) . Myostatin may add to our understanding of unchanged glycogen fractions, as myostatin levels are significantly elevated during TRT (Dubois et al., 2014; Dalbo et al., 2017) , and myostatin represents a potential key mediator of insulin resistance (Cleasby et al., 2014) . Unfortunately, there is currently no reliable myostatin assay, and this hypothesis remains to be tested.
We observed a higher fraction of lipid droplets at baseline in the TRT group compared to the placebo group, which may reflect differences in physical activity; however, mitochondrial fraction, and VO 2max at baseline were comparable between the groups, indicating similar aerobic capacity. The unchanged LD fraction during TRT in the present study was consistent with our previously published data, showing unchanged muscle mRNA levels of genes involved in lipid metabolism during TRT (Petersson et al., 2014) . Unchanged lipid fraction during TRT in the present study could be explained by the previously reported decrease in serum adiponectin during TRT (Frederiksen et al., 2012b) . Decreased adiponectin may have counterbalanced the potential beneficial direct effect of increasing testosterone levels on lipid metabolism in skeletal muscle, as recombinant adiponectin has been reported to induce muscle fatty acid oxidation (Yoon et al., 2006) .
Sedentary lifestyle is increasing in the Western world, and there is a growing interest in effects of ST. We demonstrated that intramuscular mitochondria, glycogen, and LD fractions did not change during six-month ST or three-month combined ST and TRT. Our unchanged mitochondrial content during ST was in line with previous papers investigating ST effects after three months in aging non-obese men (Flack et al., 2016) and after 14 weeks in aging adults (Parise et al., 2005) ; however, Flack et al. and Parise et al. used the citrate synthase activity as a biochemical marker for mitochondrial content. In contrast, aerobic training increased mitochondrial volume fraction after 10 weeks in aging obese men with and without T2D (Nielsen et al., 2010) and after 16 weeks in healthy elderly adults (Broskey et 552 Andrology, 2018, 6, 547-555 2014). Aerobic training combined with ST may be an effective means of ameliorating an age-related decrease in mitochondrial content, as this combination may increase mitochondrial biogenesis (Wang et al., 2011) . Interestingly, we reported a positive association between changes in glycogen fraction and changes in insulin-stimulated Rd during three months of ST. This finding suggested that strength training may contribute to improvements in insulin-mediated glucose uptake and storage capacity in aging men with lowered testosterone levels, and these data are in agreement with studies in healthy older adults (Prior et al., 2015) and insulin-resistant men (Dela et al., 2014) . Despite this association, it was not reflected by increased glycogen content in our study and may be due to dropout. Strengths and limitations may apply to the present study. The first author performed the stereological method in a blinded manner based on a recently validated methodological article by Broskey et al., (2013) . Furthermore, we used three independent modalities to assess lipid metabolism: muscle LD fraction, circulating triglycerides, and FFA. We acknowledge that eligible men were included only based on a single measurement of BioT; however, all men in the placebo group had BioT <7.3 nmol/L at reassessment at three weeks. We have previously published that reference intervals for total testosterone were similar between healthy young and aging men, in contrast, FreeT and BioT assessments were lower in aging men explained by increased SHBG levels (Frost et al., 2013) . Despite that the Vermeulen formula relevantly includes SHBG as a parameter in the estimation of BioT (Vermeulen et al., 1999) , calculated BioT is not as exact as the actual measurement of BioT. The free hormone hypothesis is challenged, and it is suggested to take the variable binding affinity of testosterone to SHBG into account through a multistep dynamic allosteric model (Ly et al., 2010; Goldman et al., 2017; Handelsman, 2017) . This study was restricted to the inclusion of aging men with lowered testosterone levels and without any known metabolic disease, and we cannot exclude more prominent results in, for example, men with T2D. In the original study design, sample size was based on the effects of TRT on LBM (Frederiksen et al., 2012a,b) . We acknowledge that our study includes a subgroup of the original cohort that will limit the power to detect the effects of TRT on intramuscular mitochondrial, glycogen, and LD fractions due to underpowering including low sample size and high dropout rate.
CONCLUSION
TRT was associated with increased total testosterone, LBM, and decreased percent body fat, whereas we found no significant changes in intramuscular mitochondrial, glycogen, and LD fractions in aging men with lowered testosterone levels. Intramyocellular mitochondria, glycogen, and LD fractions were not changed in response to six-month ST or combined three-month ST+TRT compared to placebo. However, the study was conducted with a novel and an exploratory approach, so further studies with a larger sample size are needed.
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